Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabspace Cleared to Start US Trial of ADCC Molecule in Solid Tumor Cancers

publication date: Apr 20, 2020

Mabspace Biosciences (Suzhou) was cleared by the US FDA to start trials of its novel humanized Claudin 18.2 mAb in patients with metastatic solid tumors. TST001 is a humanized high affinity anti-Claudin 18.2 antibody that kills tumor cells using an antibody-dependent cellular cytotoxicity (ADCC) mechanism. Mabspace developed TST001 with HJB, a Hangzhou biologics CMC and manufacturing company, which in 2018, merged with Mabspace to form Transcenta, a global biotech that combines antibody biotherapeutics discovery, R&D and manufacturing. In January 2020, Transcenta completed a $100 million Series B funding round. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital